Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


More PhIII Success For Acacia's Dopamine Antagonist In PONV

This article was originally published in Scrip

Executive Summary

Acacia Pharma's goal of returning dopamine antagonists to the arsenal of treatments available for post-operative nausea and vomiting (PONV) has experienced another boost following positive results from a second Phase III study, this time evaluating the use of lead product Baremsis as a prophylaxis in combination with standard antiemetics for the prevention of PONV in high-risk patients.

You may also be interested in...

Acacia Pharma's Antiemetic Baremsis A Step Closer to US Filing

Acacia Pharma has taken another step towards filing its post-operative nausea and vomiting treatment Baremsis in the US with a second Phase III trial, this time in the treatment, rather than prevention, of the condition.

UK Reimbursement Decisions Focus Mostly On Cancer

The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.

Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts

While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts